Home / Pharmaceuticals / Global Antibody Drug Conjugate Market By Drug (Kadcyla, Adcetris, Pipeline Analysis Of Antibody Drug Conjugate) - Growth, Future Prospects And Competitive Analysis, 2016 - 2024

Global Antibody Drug Conjugate Market By Drug (Kadcyla, Adcetris, Pipeline Analysis Of Antibody Drug Conjugate) - Growth, Future Prospects And Competitive Analysis, 2016 - 2024

Published: Mar 2017 | Report Code: 58379-03-17

Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. By attaching biologically active chemotherapeutic drugs, radioactive isotopes, cytokines or cytotoxins via chemical linkers with liable bonds to a monoclonal antibody directed to antigens differentially overexpressed in tumor cells, ADCs significantly improve sensitive discrimination between healthy and diseased tissue.

The report titled “Global Antibody Drug Conjugate Market- Growth, Future Prospects and Competitive Analysis, 2016–2024” offers strategic insights into the overall Antibody Drug Conjugate market along with the market size and estimates for the duration 2016 to 2024. The research study covers in-depth analysis of market segments based on drug type and different geographical region.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in global Antibody Drug Conjugate market, attractive investment proposition and market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the global Antibody Drug Conjugate market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Rest of the World

Market size and forecast for these regional and country level markets are presented in this study for the period 2014-2024. Market growth rates for the forecast period 2016-2024 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global Antibody Drug Conjugate market. Pipeline analysis of the drugs currently in the clinical trial stage is also included in the report. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global Antibody Drug Conjugate market. This report concludes with company profiles section that highlights major information about the key players engaged in global Antibody Drug Conjugate market. In-depth competitive environment analysis and historical years (2014) market size data are also provided in the report. 

Thus, the research study provides a holistic view of the global Antibody Drug Conjugate market, offering market size and estimates for the period from 2016 to 2024, keeping in mind the above-mentioned factors.

Antibody Drug Conjugate Market

1. Preface
1.1. Report Scope and Description
1.2. Research Methodology

2. Executive Summary
2.1. Global Antibody Drug Conjugate Market Snapshot
2.2. Global Antibody Drug Conjugate Market, by Geography, 2015 (Value %)

3. Global Antibody Drug Conjugate Market Analysis
3.1. Global Antibody Drug Conjugate Market Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Challenges
3.2.3. Opportunities
3.3. Attractive Investment Proposition, 2015
3.4. Competitive Landscape Assessment, By Key Market Players

4. Global Antibody Drug Conjugate Market, By Drug, 2014 – 2024 (USD)
4.1. Overview
4.2. Kadcyla
4.3. Adcetris
4.4. Pipeline Analysis of Antibody Drug Conjugate Market, 2014 – 2024 (USD)

5. Global Asthma Therapeutics Market, By Geography, 2014 – 2024 (USD)
5.1. Overview
5.2. North America
5.2.1. U.S.
5.2.2. Canada
5.3. Europe
5.3.1. U.K.
5.3.2. Germany
5.3.3. Rest of Europe
5.4. Asia Pacific
5.4.1. China
5.4.2. Japan
5.4.3. Rest of APAC
5.5. Rest of the World

6. Company Profiles
6.1. Seattle Genetics, Inc.
6.1.1. Business Description
6.1.2. Financial Health and Budget Allocation
6.1.3. Product Positions/Portfolio
6.1.4. News Coverage
6.2. F. Hoffman-La Roche
6.3. ImmunoGen, Inc.
6.4. Bayer AG
6.5. Novartis AG
6.6. Takeda Pharmaceutical Company Limited
6.7. Immunomedics, Inc.
6.8. Agensys, Inc.
6.9. Concortis Biotherapeutics
6.10. NBE-Therapeutics
6.11. Pfizer
6.12. Polytherics (An Abzena Company)
6.13. Oxford BioTherapeutics
6.14. Spirogen (MedImmune)
6.15. Others

Note:

  • Profiles of specific market players or further market segmentation, if required, shall be added to the report upon request.

Based on the type of drug, the antibody drug conjugate market is segmented into:

  • ADCETRIS
  • Kadcyla

Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. By attaching biologically active chemotherapeutic drugs, radioactive isotopes, cytokines or cytotoxins via chemical linkers with liable bonds to a monoclonal antibody directed to antigens differentially overexpressed in tumor cells, ADCs significantly improve sensitive discrimination between healthy and diseased tissue. Currently marketed drugs suffers from various stipulations like low potency, lack of specificity and adverse effects. This has forced the pharmaceutical and research companies to develop therapeutics that can overcome these barriers. Commercializing antibody drug conjugates have overcome these scenarios and improve the medical conditions. The currently marketed antibody drug conjugate drugs are Adcetris (Seattle Genetics) and Kadcyla (Genentech/Roche). Additionally there are more than 50 molecules in the pre-clinical stage. Out of these, approximately 25% are in Phase II or Phase III of development, leading to a rapidly expanding pre-clinical pipeline. With more than 190 active clinical trials, antibody-drug conjugates are gaining acceptance across the globe as they offer superior pharmacological efficiency along with minimized side effects.

Antibody Drug Conjugate Market

For the purpose of this study, the global antibody drug conjugate market is categorized as follows:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Antibody Drug Conjugate Market

The geographical segmentation of the global antibody drug conjugate market comprises North America, Europe, Asia-Pacific, and Rest of the World. In base year 2015, North America accounted for the largest market in the antibody drug conjugate market due to the presence of major pharmaceutical companies working on the development of antibody drug conjugate drugs. Moreover, one of the prime reason of North America’s dominance in the antibody drug conjugates market is the fast-track approval and commercialization of ADCs in the region as compared to other geographical regions. Europe held the second largest market for antibody drug conjugates market. Kadcyla, one of the two drugs that are marketed currently is manufactured by the Europe based pharmaceutical giant, Roche. Additionally, Europe was the second region after where the commercialization of the ADCs were approved on a fast-track basis. There are more 190+ clinical trials currently being carried on in Europe and North America. Asia pacific is anticipated to be the fastest growing segment in the antibody drug conjugate market due to the approval of ADCs in Japan, China. Kadcyla was approved and launched in the India market as premium priced drug in 2015.  Fast-track approvals of breakthrough drugs in Asia-Pacific would further drive the antibody drug conjugate market during the forecast period.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients